Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 7
Submit an article Journal homepage
136
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editors

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma

Andrew A. LaneDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USACorrespondence[email protected] [email protected]
,
Steven L. McafeeDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
,
Joanne KennedyDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
,
Christine DubeDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
,
Eyal C. AttarDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
,
Karen K. BallenDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
,
Bimalangshu R. DeyDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
,
Thomas R. SpitzerDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
&
Yi-Bin ChenDepartment of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA
 show all
Pages 1363-1366 | Received 22 Sep 2010, Accepted 10 Mar 2011, Published online: 25 May 2011

References

  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
  • Linch DC, Winfield D, Goldstone AH, Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
  • Schmitz N, Pfistner B, Sextro M, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065–2071.
  • Kim JG, Sohn SK, Chae YS, Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007;40:919–924.
  • Wadehra N, Farag S, Bolwell B, Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006;12:1343–1349.
  • Santos EC, Sessions J, Hutcherson D, Flowers C, Langston A, Waller EK. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation–a similar experience. Biol Blood Marrow Transplant 2007;13:746–747.
  • Ulrickson M, Aldridge J, Kim HT, Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009;15:1447–1454.
  • Talamo G, Claxton DF, Dougherty DW, BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant 2009;44:157–161.
  • Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21:943–960.
  • Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011 Jan 24. [Epub ahead of print].
  • Yusuf RZ, Dey B, Yeap BY, Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009;43:37–42.
  • Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:523–536.
  • Aggarwal C, Gupta S, Vaughan WP, Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006;12:770–777.
  • Dean RM, Pohlman B, Sweetenham JW, Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 2010;148:226–234.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.